118 related articles for article (PubMed ID: 38472083)
21. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
[TBL] [Abstract][Full Text] [Related]
22. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
[TBL] [Abstract][Full Text] [Related]
23. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
24. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization.
Pipa-Muñiz M; Sanmartino S; Mesa A; Álvarez-Navascués C; González-Diéguez ML; Cadahía V; Rodríguez JE; Vega F; Rodríguez M; Costilla-García SM; Varela M
BMC Gastroenterol; 2020 Jun; 20(1):166. PubMed ID: 32487071
[TBL] [Abstract][Full Text] [Related]
25. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.
Majno PE; Adam R; Bismuth H; Castaing D; Ariche A; Krissat J; Perrin H; Azoulay D
Ann Surg; 1997 Dec; 226(6):688-701; discussion 701-3. PubMed ID: 9409568
[TBL] [Abstract][Full Text] [Related]
26. CalliSpheres Drug-Eluting Bead Transcatheter Arterial Chemoembolization Presents With Better Efficacy and Equal Safety Compared to Conventional TACE in Treating Patients With Hepatocellular Carcinoma.
Xiang H; Long L; Yao Y; Fang Z; Zhang Z; Zhang Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819830751. PubMed ID: 30862264
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 μm for the Treatment of Hepatocellular Carcinoma.
Sattler T; Bredt C; Surwald S; Rust C; Rieger J; Jakobs T
Anticancer Res; 2018 Feb; 38(2):1025-1032. PubMed ID: 29374736
[TBL] [Abstract][Full Text] [Related]
28. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
30. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
[TBL] [Abstract][Full Text] [Related]
32. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
33. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
[TBL] [Abstract][Full Text] [Related]
34. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
35. Comparative Study of Drug-eluting Beads versus Conventional Transarterial Chemoembolization for Treating Peculiar Anatomical Sites of Gastric Cancer Liver Metastasis.
Xu H; Min X; Ren Y; Yang L; Liu F
Med Sci Monit; 2020 May; 26():e922988. PubMed ID: 32474569
[TBL] [Abstract][Full Text] [Related]
36. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
37. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
Ludwig JM; Zhang D; Xing M; Kim HS
Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
Zhu D; Yuan D; Wang Z; Chen S
Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
[TBL] [Abstract][Full Text] [Related]
40. Determination of risk factors for fever after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Li J; Shi C; Shi J; Song J; Wang N
Medicine (Baltimore); 2021 Nov; 100(44):e27636. PubMed ID: 34871232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]